Aromatase inhibitors

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 11, 2002, Pages 1647-1661

  Grubjesic, Simonida ^a   Moriarty, Robert M ^a   Pezzuto, John M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Aromatase; Breast cancer; Non steroidal inhibitors; Steroidal inhibitors

Indexed keywords

ALKYL GROUP; ALKYNYL GROUP; AMINOGLUTETHIMIDE; ANASTROZOLE; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ESTROGEN; EXEMESTANE; FADROZOLE; FORMESTANE; LETROZOLE; MATRIX METALLOPROTEINASE INHIBITOR; NAPHTHALENE DERIVATIVE; NITROGEN DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PRASTERONE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; RAZOXANE; RETINOID DERIVATIVE; STEROID; TAXANE DERIVATIVE; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; UNINDEXED DRUG;

BREAST CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG USE; DYSPNEA; EDEMA; ENDOCRINE DISEASE; ENDOMETRIUM CARCINOMA; ENZYME INACTIVATION; ESTROGEN SYNTHESIS; FATIGUE; HORMONE DEPENDENCE; HOT FLUSH; HUMAN; INFECTION; NAUSEA; NONHUMAN; PAIN; PATENT; POSTMENOPAUSE; REVIEW; STRUCTURE ACTIVITY RELATION; SWEATING; WEIGHT GAIN;

EID: 0036848634     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.11.1647     Document Type: Review

References (59)

1. BRODIE A, NJAR VCO: Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications. J. Steroid Biochem. Molec. Biol. (1998) 66:1-10.
2. BRODIE A, NJAR VCO: Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. Drugs (1999) 58:233-255.
3. RECANATINI M, CAVALLI A, VALENTI P: Nonsteroidal aromatase inhibitors: recent advances. Med. Res. Rev. (2002) 22:282-304.
4. LEPHART ED: A review of brain aromatase cytochrome P450. Brain Res. Rev. (1996) 22:1-26.
5. BRODIE A, LONG B: Aromatase inhibition and inactivation. Clin. Cancer Res. (2001) 7:S4343-S4349.
6. BRODIE A, LONG B, LU Q: Aromatase expression in the human breast. Breast Cancer Res. Tr. (1998) 53:S85-S91.
7. SANTEN RJ, MARTEL J, HOAGLAND M et al.: Demonstration of aromatase activity and its regulation in breast tumor and benign breast fibroblast. Breast Cancer Res. Tr. (1998) 53:S93-S99.
8. BRODIE AMH, LU Q, LONG B: Aromatase and cox-2 expression in human breast cancer. J. Steroid Biochem. (2001) 607:1-7.
9. BANTING L, NICHOLLS PJ, SHAW MA, SMITH HJ: Recent developments in aromatase inhibition as a potential treatment for oestrogen-dependent breast cancer. Progr. Med. Chem. (1989) 26:253-298.
10. BANTING L: Inhibition of aromatase. Progr. Med. Chem. (1996) 33:147-184.
11. SERALINI G, MOSLEMI S: Aromatase inhibitors: past, present and future. Mol. Cell. Endocrinol. (2001) 178:117-131.
12. NUMAZAWA M, OSHIBE M, YAMAGUCHI S, TACHIBANA M: Time-dependent inactivation of aromatase by 6-alkylandrosta-1,4-diene-3,17-dione. Effects of length and configuration of the 6-alkyl group. J. Med. Chem. (1996) 39:1033-1038.
13. NUMAZAWA M, OSHIBE M, YAMAGUCHI S, TACHIBANA M: Enzymic aromatization of 6-alkyl-substitute androgens, potent competitive and mechanism-based inhibitors of aromatase. Bioch. J. (1998) 329:151-156.
14. AKKANI A, PATERLINI G, GLEASON WB et al.: 6β-propynyl-substituted steroids: mechanism-based enzyme-activated irreversible inhibitors of aromatase. J. Med. Chem. (1997) 40:3263-3270.
15. KITZ R, WILSON IB: Esters of methansulfonic acid as irreversible inhibitors of acetylcholinesterase. J. Biol. Chem. (1962) 237:3425-3449.
16. 2. Arch. Pharm. Med. Chem. (1996) 329:251-256.
17. WACHTER GA, HARTMANN RW, SERGEJEW TF et al.: Tetrahydronaphtalenes: influence of heterocyclic substituents on inhibition of steroidogenic enzymes P450 arom and P450 17. J. Med. Chem. (1996) 39:834-841.
18. NJAR VC, BRODIE AM: Inhibitors of 17α-hydroxylase/17, 20-lyase (CYP17): potential agents for the treatment of prostate cancer. Curr. Pharm. Des. (1999) 5:163-180.
19. HARTMANN RW, EHMER PB, HAIDAR S et al.: Inhibition of CYP17, a new strategy for the treatment of prostate cancer. Arch. Pharm. (2002) 335:119-128.
20. BRUEGGEMEIER RW: Aromatase, aromatase inhibitors, and breast cancer. Am. J. Ther. (2001) 8:333-344.
21. RAMAN JD, SCHLEGEL PN: Aromatase inhibitors for male infertility. J. Urol. (2002) 167:624-629.
22. SANTEN RJ, PETRONI GR, FISCH MJ et al.: Use of aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma. Cancer (2001) 92:2095-2101.
23. BULUN SE, NOBLE SL, TAKAYAMA K et al.: Endocrine disorders associated with inappropriately high aromatase expression. J. Steroid Biochem. Molec. Bio.l (1997) 61:133-139.
24. TURNER KJ, MORLEY M, ATANASSOVA N, SWANSTON ID, SHARPE RM: Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. J. Endocrinol. (2000) 164:225-238.
25. BRAUNSTEIN GD: Aromatase and gynecomastia. Endocr. Relat. Cancer (1999) 6:315-324.
26. MURRAY R. Role of anti-aromatase agents in postmenopausal advanced breast cancer. Cancer Chemother. Pharmacol. (2001) 48:259-265.
27. KELLOFF GJ, SIGMAN CC, GREENWALD P: Cancer chemoprevention: progress and promise. Eur. J. Cancer(1999) 35:1755-1762.
28. LUBET RA, STEELE VE, CASEBOLT TL, ETO I, KELLOFF GJ, GRUBBS CJ: Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosurea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis (1994) 15:2775-2780.
29. GUNSON DE, STEELE RE, CHAU RY: Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor. Br. J. Cancer (1995) 72:72-75.
30. KELLOFF GJ, LUBET RA, LIEBERMAN R et al.: Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomark. Prev. (1998) 7:65-78.
31. VAN LANDEGHEM AAJ, POORTMAN J, NABUURS M et al.: Endogenous concentration and subcellular distribution of estrogen in normal and malignant human breast tissue. Cancer Res. (1985) 45:2900-2906.
32. VERMEULEN A, DESLYPERE JP, PARIDAENS R et al.: Aromatase, 17β hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal breast tissue in postmenopausal women. Eur. J. Cancer Clin. Oncol. (1986) 22:515-525.
33. YUE W, WANG J, HAMILTON CJ et al.: In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res. (1998) 58: 927-932.
34. GRADISHAR WJ, JORDAN VC: Clinical potential of new antiestrogens. J. Clin. Oncol. (1997) 15:840-852.
35. WALKER RA, DEARING SJ: Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res. Tr. (1999) 53:167-176.
36. RICHARDS JA, PETREL TA, BRUEGGEMEIER RW: Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells. J. Steroid Biochem. Molec. Biol. (2002) 80:203-212.
37. SLAMON DJ, GODOLPHIN W, JONES LA: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244:707-712.
38. BRUEGGEMEIER RW: Aromatase inhibitors in breast cancer therapy. Expert Rev. Anticancer Ther. (2002) 2:181-191.
39. SHARPE RM: The roles of oestrogen in the male. Trends Endocrin. Met. (1998) 9:371-377.
40. MAHLER C, VERHELST J, DENIS L: Clinical pharmacocinetics of the antiandrogens and their efficacy in prostate cancer. Clin. Pharmacokinet. (1998) 34:405-417.
41. COMHAIRE FH, ROMBAUTS L, VEREECKEN A et al: Inhibin and steroid responses to testicular stimulation in normal men. Human Rep. (1995) 10:1740-1744.
42. AHOKOSKI O, IRJALA K, HUHTALA S et al.: A double-blind study of MPV-2213ad, a novel aromatase inhibitor, in healthy male subjects. Eur. J. Clin. Pharmacol. (1999) 55:27-34.
43. AHOKOSKI O, IRJALA K, TAALIKKA M et al.: Pharmacokinetics of finrozole (MPV-2213ad), a novel selective aromatase inhibitor, in healthy man. Br. J. Clin. Pharmacol. (2001) 52:702-704.
44. KARJALAINEN A, KALAPUDAS A, SÖDERVALL M et al.: Synthesis of new potent and selective aromatase inhibitors based on long-chained diarylalkylimidazole and diarylalkyltriazole molecule skeletons. Eur. J. Pharm. Sci. (2000) 11:109-131.
45. BUZDAR A. A summary of second-line randomized studies of aromatase inhibitors. J. Steroid Biochem. Molec. Biol. (2001) 79:109-114.
46. MOURIDSEN H, GERSHANOVICH M, SUN Y et al.: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast cancer Group. J. Clin. Oncol. (2001) 19:2596-606.
47. RAGAZ J: Adjuvant trials of aromatase inhibitors: determining the future landscape of adjuvant endocrine therapy. J. Steroid Biochem. Molec. Biol. (2001) 79:133-141.
48. GOSS PE: Preliminary data from ongoing adjuvant aromatase inhibitor trials. Clin. Cancer Res. (2001) 7:S4397-S4401.
49. GOSS PE, STRASSER K: Tamoxifen resistant and refractory breast cancer. Drugs (2002) 62:957-966.
50. ELLIS MJ, COOP A, SINGH B et al.: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen-receptor positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol. (2001) 19:3808-3816.
51. EIERMAN W, PAEPKE S, APPFELSTAEDT J et al.: Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized multicenter study. Ann. Oncol. (2001) 12:1527-32.
52. LONNING PE, KRAGH LE, ERIKSTEIN B et al.: The potential for aromatase inhibition in breast cancer prevention. Clin. Cancer Res. (2001) 7:S4423-S4428.
53. GOSS PE, STRASSER K: Chemoprevention with aromatase inhibitors-trial strategies. J. Steroid Biochem. Molec. Biol. (2001) 79:143-149.
54. FABIAN CJ, KIMLER BF: Beyond tamoxifen: new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention. Ann. NY Acad. Sci. (2001) 952:44-59.
55. FOWLER KA, GILL K, KIRMA K et al.: Overexpression of aromatase leads to development of testicular Leydig cell tumors. Am. J. Pathol. (2000) 156:347-355.
56. FEUILLAN P, MERKE D, LESCHEK EW et al.: Use of aromatase inhibitors in precocious puberty. Enocr. Relat. Cancer (1999) 6:315-324.
57. BULUN SE, NOBLE SL, TAKAYAMA K et al.: Endocrine disorders associated with inappropriately high aromatase expression. J. Steroid Biochem. Molec. Biol. (1997) 61:133-139.
58. BULUN SE, YANG S, FANG Z et al. Estrogen production and metabolism in endometriosis. Ann. NY Acad. Sci. (2002) 955:75-85.
59. FIORELI G, PISCARIELLO L, MARTINETI V et al.: Estrogen synthesis in human colon cancer epithelial cells. J. Steroid. Biochem. Molec. Biol. (1999) 71:223-230.